FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

Trial Profile

FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms FAST
  • Most Recent Events

    • 06 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 08 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
    • 13 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top